5-ASA Induced Recurrent Myopericarditis and Cardiac Tamponade in a Patient with Ulcerative Colitis

Sonu, Irene; Wong, Robert J.; Rothenberg, Michael E.

doi:10.1007/s10620-013-2566-4

Cited by 17 publications

(13 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The patients described in these reports frequently, but not inevitably, presented with fever (Table 1), chest pain, 3,[6][7][8]11,[13][14][15][16][17]19,23,24,27,30,31,[36][37][38]40,[44][45][46][48][49][50]52,53 and shortness of breath. 7,16,17,24,29,30,32,36,46,52 The symptom of lassitude or fatigue was also common at the time of presentation.…”

Section: What Should Alert the Clinician To The Possibility Of Cardiamentioning

confidence: 99%

“…7,16,17,24,29,30,32,36,46,52 The symptom of lassitude or fatigue was also common at the time of presentation. On physical examination, a pericardial rub 6,12,14,15,20,23,52,53 was sometimes detected, which may have reflected the extent of pericardial involvement. A concurrent pleural rub has been reported, but rarely.…”

Section: What Should Alert the Clinician To The Possibility Of Cardiamentioning

confidence: 99%

“…Eosinophilia has sometimes been noted in the leukocyte differential analysis. 6,25,33,37,42,44,53 Evidence of inflammation was frequently indicated by elevation of the erythrocyte sedimentation rate (Table 1) [13][14][15]27,30,32,36,38,40,43,46,[48][49][50][51] Elevated N-terminal pro-brain natriuretic peptide concentrations have also been found. 42,44 The presence or absence of any or all of the above symptoms and signs does not confirm the role of 5-ASA in the origin of the condition.…”

Section: What Should Alert the Clinician To The Possibility Of Cardiamentioning

confidence: 99%

See 2 more Smart Citations

5-Aminosalicylic Acid–Associated Myocarditis and Pericarditis: A Narrative Review

Brown

2016

CJHP

View full text Add to dashboard Cite

RÉSUMÉContexte : L'emploi de médicaments à base d'acide 5-aminosalicylique (5-AAS) peut causer un effet indésirable rare, mais potentiellement mortel qui se traduit par l'inflammation du myocarde (myocardite) ou du péricarde (péricardite) ou de ces deux éléments du système cardiaque (myopéricardite). Il est important d'établir rapidement que l'inflammation est imputable à l'AAS afin de prévenir la progression de cet effet indésirable. Objectif : Fournir aux cliniciens de l'information les aidant à reconnaître les signes et symptômes d'une inflammation cardiaque causée par le 5-AAS et les caractéristiques de la thérapie soupçonnée ainsi qu'à déterminer l'approche thérapeutique adéquate. Sources des données, sélection des études et extraction des données :La base de données Embase a été interrogée, pour la période allant de 1974 au 17 juillet 2015, afin de trouver des descriptions publiées de cas d'inflammation cardiaque causée par des médicaments contenant du 5-AAS. Les termes utilisés pour la recherche comprenaient les noms d'agents précis ainsi que les termes désignant différents types d'inflammation cardiaque. La langue n'était pas un critère pour l'admissibilité des articles à la présente revue narrative. Résultats : Il n'y a pas de symptôme, de signe, d'examen de laboratoire ou de cortège de symptômes et de signes qui soit pathognomonique d'une toxicité myocardique ou péricardique causée par le 5-AAS. De même, il n'y a pas de résultat de laboratoire, d'électrocardiogramme ou d'échocar-diogramme, seul ou en association, qui puisse attribuer la cause de symptômes non spécifiques au 5-AAS. Cependant, la plupart des patients présentent des douleurs thoraciques, une dyspnée et de la fièvre au cours des 28 premiers jours suivant l'amorce du traitement par le 5-AAS. L'examen physique, l'électrocardiographie et l'imagerie diagnostique permettent d'obtenir des résultats qui indiquent une myocardite, avec ou sans péricardite. L'interruption rapide du traitement par le 5-AAS permet la disparition des symptômes en quelques jours, sans avoir à recourir à un traitement d'appoint. La réintroduction de toute préparation à base de 5-AAS comporte un risque élevé de récurrence de l'inflammation. Conclusions : Tout patient affichant des douleurs thoraciques, de la dyspnée ou de la fièvre dans les 28 jours suivant l'amorce d'un traitement avec une préparation contenant du 5-AAS doit être considéré comme présentant une inflammation causée par un médicament. Il faut interrompre immédiatement le traitement par le 5-AAS jusqu'à ce que d'autres causes puissent être confirmées ou infirmées. Si l'on ne trouve pas d'autre cause aux symptômes, le traitement par le 5-AAS ne doit pas être recommencé.

show abstract

Section: What Should Alert the Clinician To The Possibility Of Cardiamentioning

confidence: 99%

Section: What Should Alert the Clinician To The Possibility Of Cardiamentioning

confidence: 99%

Section: What Should Alert the Clinician To The Possibility Of Cardiamentioning

confidence: 99%

See 1 more Smart Citation

5-Aminosalicylic Acid–Associated Myocarditis and Pericarditis: A Narrative Review

Brown

2016

CJHP

View full text Add to dashboard Cite

show abstract

“…As mentioned above, drugs can be involved in the pathogenesis of IBD related cardiac manifestations. It must be noted that most reports of myopericarditis complicating IBD involve concomitant aminosalicylate therapy, making it difficult to exclude a drug-related effect (7)(8)(9)(10). Several mechanisms have been proposed for mesalamine-induced myopericarditis: a) IgE-mediated allergic reaction; b) direct cardiac toxicity; c) cell-mediated hypersensitivity; and d) humoral antibody response.…”

Section: Discussionmentioning

confidence: 99%

Mesalamine-induced myopericarditis - A case report

Bernardo

Araújo-Correia

2016

Rev Esp Enferm Dig

View full text Add to dashboard Cite

Myopericarditis has occasionally been reported as a side effect of mesalamine in patients with inflammatory bowel disease. We present a 20-year-old woman with ulcerative colitis admitted with chest pain. After thorough investigation she was diagnosed with myopericarditis potentially related to mesalamine. There was complete clinical and laboratorial recovery following drug withdrawal. Although uncommon, the possibility of myopericarditis should be considered in patients with inflammatory bowel disease presenting with cardiac complaints. Early recognition can avoid potential life-threatening complications.

show abstract

“…Although many theories exist regarding the cause of UC, none has been proved (Sonu et al, 2013;Trivedi & Jena, 2012. Currently, some studies indicated that immunological abnormality as a part of interstinal mucosa may cause UC (Ardizzone et al, 2006;Römkens et al, 2012).…”

Section: Introductionmentioning

confidence: 99%

Novel pH-sensitive hydrogels for 5-aminosalicylic acid colon targeting delivery:in vivostudy with ulcerative colitis targeting therapy in mice

et al. 2015

View full text Add to dashboard Cite

(2016) Novel pH-sensitive hydrogels for 5-aminosalicylic acid colon targeting delivery: invivo study with ulcerative colitis targeting therapy in mice, Drug Delivery, 23:6, 1926-1932, DOI: 10.3109/10717544.2014 The Central Hospital of Xi' an Huashan, Xi' an, China AbstractCurrent guidelines recommend patients with active and mild-to-moderate ulcerative colitis (UC), who have received initial therapy with 5-aminosalicylic acid (5-ASA). In this study, a novel drug delivery vehicle achieved by pH-sensitive hydrogels was applied to 5-ASA. In our previous work, a novel P(CE-MAA-MEG) pH-sensitive hydrogel was successfully synthesized by the heatinitiated free radical polymerization method. The aim of this study is to investigate its sitespecific delivering of drugs to the colon and evaluate its colon-targeting characteristic in vivo. 5-ASA was chosen as a model drug and successfully loaded in the hydrogel. In vitro investigations were carried out to evaluate its release process. Above all, animal treatment results reveal an obvious effect on the UC healing. Therefore, all results suggested that the developed 5-ASA-P(CE-MAA-MEG) hydrogel (5-ASA-GEL) as a colon-targeting vector might have a great potential application in the UC therapy.

show abstract

5-ASA Induced Recurrent Myopericarditis and Cardiac Tamponade in a Patient with Ulcerative Colitis

Cited by 17 publications

References 9 publications

5-Aminosalicylic Acid–Associated Myocarditis and Pericarditis: A Narrative Review

5-Aminosalicylic Acid–Associated Myocarditis and Pericarditis: A Narrative Review

Mesalamine-induced myopericarditis - A case report

Novel pH-sensitive hydrogels for 5-aminosalicylic acid colon targeting delivery:in vivostudy with ulcerative colitis targeting therapy in mice

Contact Info

Product

Resources

About